The preimplantation genetic testing market has seen considerable growth due to a variety of factors.
• The market size of preimplantation genetic testing has been expanding at an accelerated pace recently. The forecast suggests an increase from $0.83 billion in 2024 to $0.92 billion in 2025, with an expected compound annual growth rate (CAGR) of 11.6%.
The historic period’s growth is a reflection of factors such as the rise in genetic disorder cases, heightened awareness about genetic testing, an expansion in prenatal testing options, growing interest in personalized medicine and the prioritization of preventive healthcare.
The preimplantation genetic testing market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of preimplantation genetic testing is projected to experience rapid expansion in the coming years. It is predicted to increase to $1.41 billion in 2029 with a compound annual growth rate (CAGR) of 11.2%.
The forecasted growth can be linked to the surge in fertility clinics, expansion in genetic counseling services, a rise in advanced maternal age, enhanced accessibility to sophisticated genetic testing platforms, and broader uses of PGT. Significant trends for the forecast period encompass the adoption of cutting-edge sequencing technologies, the introduction of extensive genetic panels, the progression in non-invasive testing methods, improvements in embryo culture systems, and advancements in genetic editing technologies.
Advancements in in vitro fertilization (IVF) procedures are projected to spur the development of the preimplantation genetic testing market. IVF procedures, which involve the fertilization of an egg outside the body and its subsequent positioning in the uterus, are seeing an uptick due to enhancements in reproductive technology, burgeoning infertility rates, and amplified public consciousness. This surged interest in IVF is fueling the preimplantation genetic testing market by creating a greater need for genetic assessment of embryos prior to implantation. For example, the Society for Assisted Reproductive Technology, a US organization, reported in April 2024 that 91,771 newborns were brought into the world through IVF in 2022. Thus, the escalation in IVF procedures is propelling the preimplantation genetic testing market.
The preimplantation genetic testing market covered in this report is segmented –
1) By Procedure: Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis
2) By Product: Reagents And Consumables, Instruments, Software
3) By Technology: Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In Situ Hybridization (FISH), Other Technologies
4) By Application: Chromosomal Abnormalities, Aneuploidy Screening, X-Linked Diseases, Embryo Testing, Human Leukocyte Antigen (HLA) Typing, Other Applications
5) By End User: Hospitals, Fertility Centers, Diagnostic Centers, Research Centers And Academic Labs
Subsegments:
1) By Preimplantation Genetic Screening (PGS): Array Comparative Genomic Hybridization (aCGH), Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH)
2) By Preimplantation Genetic Diagnosis (PGD): Monogenic Disorders Testing, Chromosomal Abnormalities Testing, HLA Typing for Stem Cell Transplantation
Leading firms in the preimplantation genetic testing market are innovating advanced next-generation sequencing (NGS) tools to boost precision, efficacy, and speed in genetic screening, facilitating a more thorough diagnosis and informed choices for potential parents. NGS tools quicken genetic research through fast, extensive analysis of DNA and RNA. They offer in-depth knowledge regarding genetic variants and gene expression, enhancing accuracy and paving the way for personalized medicine. For example, Thermo Fisher Scientific, a biotechnology company based in the US, introduced the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit in July 2023. These advanced next-generation sequencing tools are designed for improving IVF and ICSI research. The kits make sample processing to aneuploidy analysis workflows more efficient by using groundbreaking technology on the ion torrent genexus integrated sequencer. This technological breakthrough has greatly led to the advancement in the preimplantation genetic testing market by enriching embryo screening and boosting success rates in assisted reproductive technologies.
Major companies operating in the preimplantation genetic testing market are:
• Thermo Fisher Scientific
• Abbott Laboratories
• Laboratory Corporation of America Holdings
• Agilent Technologies Inc.
• Illumina Inc.
• Revvity Health Science Inc.
• CooperSurgical Inc.
• Natera Inc.
• Progyny Inc.
• Myriad Genetics Inc.
• Fulgent Genetics Inc.
• Invitae Corporation
• Takara Bio Inc.
• MedGenome Labs Ltd.
• Genea Limited
• Ovation Fertility
• Juno Genetics Ltd.
• Invicta Genetics
• Progenesis
• Bioarray SL
• PacGenomics
• Reproductive Genetic Innovations LLC
• SEQUENCE46 LLC
North America was the largest region in the preimplantation genetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preimplantation genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.